Machine Learning

Target RWE's strategic hire of NoviSci co-founder Alan Brookhart signals a major push to master regulatory-grade real-world evidence. What does this mean?

Groundbreaking lymphoma data and a strategic acquisition position Natera to dominate the liquid biopsy market, challenging old standards and creating new value.

Vancouver's SimplyAsk.ai and Mexican telecom giant Axtel partner to tackle AI's high failure rate, aiming to unlock a multi-billion dollar market.

Beyond the award, Pariveda's use of generative AI to modernize legacy systems reveals a powerful new playbook for enterprise transformation and value.

With its new 'Eagle Line' pilot facility online, QuantumScape takes a leap toward the EV future. We analyze the tech, the risks, and the competition.

A key safety milestone for Opus Genetics' OPGx-BEST1 gene therapy trial offers a glimmer of hope for thousands facing progressive vision loss from Best disease.

With validated Phase 1b data, ONL Therapeutics' novel drug aims to protect vision cells, not just slow disease, in a challenge to current GA therapies.

Beyond the press release: How two strategic hires signal Plus Therapeutics' aggressive push to commercialize its CNSide platform and capture a $6B market.

A new lab system combines speed, multiplexing, and regulatory trust, promising to accelerate drug development and deepen our biological understanding.

A new alliance explores how inanimate microbes, or postbiotics, could become a novel weapon in oncology, starting with breast cancer research.

A new initiative empowers local leaders to deploy a data-backed 'catch-up' learning method, aiming to solve Africa's foundational education crisis.

For those with severe PTSD and depression, hope is scarce. Biotech firm Compass Pathways is pioneering a psilocybin treatment that could change everything.

Independent 2025 endpoint security tests expose the top performers and true costs, offering CISOs a clear guide to navigating a complex market.

For patients with slow-growing lymphoma, "watch-and-wait" can be agonizing. A novel immunotherapy is showing promise in replacing anxiety with action.

Advanced chip packaging is the unsung hero of the AI revolution, with a market set to explode. But can the industry sustain its billion-dollar habit?

With its AI & Autonomy Day, Rivian is betting its future on software. Investors are watching to see if its tech can deliver a true competitive edge.

Imviva Biotech's 'ready-to-use' CAR-T therapy shows breakthrough results, offering new hope and eliminating life-threatening waits for leukemia patients.

Following a major clinical trial win, Kymera Therapeutics seeks $500M. We break down the high-stakes strategy behind funding a new era of medicine.

New clinical data reveals a breakthrough 'off-the-shelf' cell therapy that could treat severe autoimmune diseases by re-engineering cellular identity.

When a 'living drug' for cancer fails, hope fades. A new biologic aims to repaint the target, giving patients' own immune cells a second chance to win.